

# **Rapid establishment of public sector COVID-19 test and treatment programs across seven low- and middle-income countries: Implementation strategies and program monitoring results**

**Short title:** Public sector COVID-19 test and treatment programs in 7 low- and middle-income countries

**Authors:** Caroline E. Boeke (CHAI US), Nervine Hamza (CHAI US), Chukwuemeka Agwuocha (CHAI Nigeria), Okechukwu Amako (CHAI US), Khamsay Detlueyay (Department of Healthcare and Rehabilitation, Ministry of Health, Laos), Michelle Gao (CHAI US), Bridget C. Griffith (CHAI US), Yamikani Gumulira (CHAI Malawi), Elina Urli Hodges (Duke University), Jessica Joseph (CHAI US), Norman Lufesi (Malawi Ministry of Health), Emily Macharia (Duke University), Nyuma Mbewe (Zambia National Public Health Institute), Elizabeth McCarthy (CHAI US), Faustina O. Mintah (CHAI Ghana), Moses Mukiibi (Clinical Pharmacist, Quality Assurance Division, DPNM Ministry of Health, Uganda), Mwaba Mulenga (CHAI Zambia), Alida Ngwije (CHAI Rwanda), Lawrence Ofori-Boadu (Institutional Care Division, Ghana Health Service), Ijeoma Uzundu Okoli, (Federal Ministry of Health, Nigeria), Sompasong Phongphila (CHAI Laos), Christian Ramers (CHAI US), Sean Regan (CHAI US), Evarist Twinomujuni (CHAI Uganda), Edson Rwagasore (Division Manager for Public Health Surveillance, Emergency Preparedness and Response, Rwanda Biomedical Center), Jessica Tebor (CHAI US), Krishna Udayakumar, (Duke University) on behalf of the COVID-19 Treatment QuickStart Consortium

## ABSTRACT

The COVID-19 Treatment QuickStart Consortium[1] worked with governments in 7 low- and middle-income countries, Ghana, Laos, Malawi, Nigeria, Rwanda, Uganda, and Zambia, to implement COVID-19 test-and-treat programs at 776 health facilities, including training over 5,000 staff and facilitating a donation of 11,300 courses of the oral antiviral nirmatrelvir/ritonavir for treatment. This paper describes the process of implementing COVID-19 test-and-treat programs in each country, provides aggregate program monitoring data on numbers tested and treated from program initiation through June 2024, and analyzes program enablers and challenges. Between country-level program initiation (ranging from December 2022 for Zambia to September 2023 for Uganda) and June 2024, a total of 731,970 SARS-CoV-2 tests were conducted. Of 6,724 positive tests, a subset were documented to meet eligibility criteria for nirmatrelvir/ritonavir initiation, and 3,041 patients were prescribed nirmatrelvir/ritonavir. The largest number of prescriptions was in Zambia. Program enablers included decentralization of services, task-shifting from higher to lower health worker cadres, increased access to point of care antigen tests - including self-tests, and the integration of COVID-19 with other health services. Challenges included COVID-19 de-prioritization at the time of program rollout, test commodity stockouts and expiries, and dwindling national surveillance efforts. Learnings from rapid initiation and scale-up of COVID-19 test-and-treat programs in these 7 countries can be used to inform future pandemic preparedness strategies in LMICs.

**Key words:** pandemic preparedness, COVID-19, test-and-treat, Africa, low- and middle-income countries, implementation science, nirmatrelvir/ritonavir

## Introduction

The COVID-19 pandemic has led to over 9 million deaths globally as of June 2024.[2] Effective vaccines[3] and treatments[4] have helped prevent a higher death toll. However, over the course of the pandemic, low- and middle-income countries (LMIC) experienced delayed and more limited access to diagnostics, vaccines, and treatment.

In particular, nirmatrelvir/ritonavir, an oral antiviral demonstrated to reduce risk of hospitalization and death due to COVID-19,[4] was made available in high income countries after US FDA Emergency Use Authorization in December 2021, but the first reported delivery to LMIC by global buyers did not take place for another 15 months.[5, 6] Nirmatrelvir/ritonavir is intended for use through a test-and-treat model, in which individuals who test positive for COVID-19, have a mild/moderate infection, and are defined as high-risk (including older individuals or those with co-morbidities such as HIV, hypertension, cardiac disease, diabetes) are initiated on treatment within 5 days of symptom onset. Treatment with this 5-day regimen in this group of individuals reduces the risk of progression to severe/critical COVID-19, mitigating hospitalizations and death.[7-10] Limited data is available in LMIC contexts on real-world COVID-19 test-and-treat program implementation and utilization of nirmatrelvir/ritonavir.

The COVID-19 Treatment QuickStart Consortium worked with governments in 7 LMIC (Ghana, Laos, Malawi, Nigeria, Rwanda, Uganda, and Zambia) to develop and roll out COVID-19 test-and-treat programs from 2022-2024. Support included facilitating a nirmatrelvir/ritonavir donation as well as providing technical assistance on program implementation and monitoring and evaluation (M&E). An evaluation was conducted across the program countries; details on the

evaluation methodology have been previously published.[11] This manuscript aims to describe program implementation approaches across the 7 countries, present aggregate M&E results across the 7 countries, highlight key program enablers and challenges, and facilitate sustainability planning for COVID-19 testing and treatment programs.

## **Program Implementation Approach**

### *The QuickStart Consortium*

The COVID-19 Treatment QuickStart Consortium, a partnership between Duke University, AmeriCares, the Clinton Health Access Initiative, and the COVID Collaborative, received funding from Open Society Foundations, Pfizer, and the Conrad N. Hilton Foundation to introduce donated nirmatrelvir/ritonavir in 10 LMICs and provide technical assistance to governments in implementing COVID-19 test-and-treat programs. As of July 2024, 8 of the initial 10 countries had moved forward with approving the importation of the drug and implementing programs, and 7 had M&E data available.

### *COVID-19 Test-and-Treat Program Approach*

Broadly, implementation of test-and-treat programs for COVID-19 through the QuickStart program consisted of the following:

1. **Collaboration on guidelines development and implementation planning** including development of national policies, clinical guidelines, program rollout strategies, and national training programs, as well as generation of standard operating procedures (SOPs) for test

operation and administration, results interpretation, quality assurance/quality control, treatment initiation, drug-drug interaction, and reporting.

2. **Supply and distribution planning for decentralized testing with point-of-care antigen**

**(POC-Ag) tests** that have received emergency use authorization by stringent regulatory authorities (SRAs) or World Health Organization (WHO) Prequalification, and which are nationally approved for clinical use.

3. **Facilitating the donation of antiviral treatment** (nirmatrelvir/ritonavir) and in some

countries, self-tests. Nirmatrelvir/ritonavir received emergency use authorization (and more recently, full US Food and Drug Administration approval) by SRAs, and which is nationally approved for clinical use. QuickStart provided support obtaining rapid regulatory waivers or approvals, and in-country importation.

4. **Training of healthcare workers on COVID-19 diagnostics and clinical care, and**

**equipping health facilities to implement test-and-treat** including a training of trainers, support to cascaded training to health facilities, ongoing site mentorship, and support to facilities in mapping patient flow.

5. **Support to national monitoring and evaluation systems** including, 1) introduction of new

facility registers to track patient-level information related to the individuals tested and treated through these programs, and 2) implementation of data management solutions to facilitate monitoring of test-and-treat for national program management and integration of data into existing country-level COVID-19 dashboards, as available. Paper-based or electronic registers were initiated at facilities which tracked data including patient characteristics, POC-Ag test and results, antiviral treatment eligibility, treatment regimen, treatment initiation dates and patient outcomes.

6. **Quality Control (QC) activities for post market surveillance**, supporting Ministries of Health (MOH) to ensure adequate pharmacovigilance systems in place to ensure reporting of serious adverse events (SAEs) associated with nirmatrelvir/ritonavir.

7. **Program advocacy at the community level** including development of information, education, and communication (IEC) materials aimed to educate community members on availability of test-and-treat at local facilities and eligibility criteria for treatment.

QuickStart was the first to establish COVID-19 test-and-treat programs in four countries (Laos, Nigeria, Uganda, Zambia); three countries (Ghana, Malawi, Rwanda) were conducting test-and-treat activities outside of QuickStart. Of note, some countries were also supporting COVID-19 test-and-treat work outside of the QuickStart program.

### *Ethics Statement*

The data presented in this manuscript came from aggregate sources rather than patient-level data; authors could not identify individual participants. However, this study was approved by the Duke University Institutional Review Board (Pro00111388). Consent was not obtained due to participant anonymity.

### **Implementation Highlights by Country**

Key characteristics of each country's COVID-19 test-and-treat program are provided in Table 1. All facilities provided COVID-19 treatment free of charge. Most facilities were public sector sites; however, some private facilities were included in Zambia and Nigeria's programs which agreed to provide services free of charge. Specific country program details are provided below.



145 **Table 1. Characteristics of National Public Sector COVID-19 Test and Treat Programs by Country, as of June 2024**

	Ghana	Laos	Malawi	Nigeria	Rwanda	Uganda	Zambia
<b>Program leadership and policies</b>							
National program leadership	Institutional Care Division, Ghana Health Service	Department of Healthcare and Rehabilitation, Ministry of Health	Clinical Services Team, Curative & Medical Rehabilitation Services Directorate, Ministry of Health	Department of Hospital Services, Federal Ministry of Health and the Nigeria Centre for Disease Control and Prevention	Pandemic Division, Rwanda Biomedical Centre	Department of Clinical Services, Ministry of Health	Infectious Disease and Clinical Care Department, Ministry of Health
National clinical and testing guidelines available	Yes[12]	Yes[13]	Yes[14]	Yes[15, 16]	Yes[17]	Yes[18]	Yes[19]
<b>Procurement</b>							
Originator nirmatrelvir/ritonavir registered in country	Yes	No	No	No	No	No	No
Generic nirmatrelvir/ritonavir registered in country (WHO prequalified)	No	Yes	Yes	No	No	No	No
Procurement of diagnostics	Both domestically procured (Global Fund) and donations from development partners	Both domestically procured and donations	Both domestically procured (Global Fund) and donations from partners	Both domestically procured (Global Fund) and donations from partners	Donated	Both domestically procured (Global Fund) and donations from partners	Both domestically procured (Global Fund) and donated by partners
Date first drugs arrived in country	March 2023	February 2023	March 2023	April 2023	February 2023	June 2023	December 2022
Donation quantity through QuickStart program	1000	1500	700	2,600	1,000	500	4,000
<b>Testing program</b>							
Self-testing available	No	Yes	No	No	Previously available	No (But provided for in the revised testing guidelines)	No
Testing available outside of health facilities	No	Yes	Yes, but only for healthcare workers	Yes	Yes	Yes	Yes, by trained community-based volunteers
Mass testing campaigns conducted by government	No	Yes	Yes, as a study in 2022	Yes	Yes	No	No
Bi-directional testing	Yes in some facilities. ILI/C-19 and TB/C-19	Yes (with ILI/SARI and TB)	No	Yes, Malaria/C-19, HIV/C-19, TB/C-19	Yes	No	Yes, TB/C-19
Test cost to users	Free	Free	Free	Free	Free	Free	Free
<b>National program management</b>							



Stock management system / process	Push distribution mechanism using the last mile distribution cycle from the Supply, Stores and Drug Management Division of Ghana Health Service to regional medical stores	National eLMIS (mSupply system) used at all warehouse levels to manage stock. Department of Healthcare and Rehabilitation creates distribution plan for treatment; National Center of Laboratory and Epidemiology manages test distribution. The Medical Product and Supply Center oversees stock management and distribution	Test kits: pull system used and the diagnostic department are responsible for distribution  Treatment: push system used based on consumption data. The national PSM manages the distribution	Push distribution strategy from national Central Medical Store to states; consumption reports used to monitor supply	Distributed to Rwanda Biomedical Supply (RMS) branches based at each district to serve health facilities in catchment area. Hospitals hold treatment and deliver to health centers when there are positive patients.	Quantification and Procurement Unit (QPPU) of the Department of Pharmaceuticals and Natural Medicines (DPNM) Ministry of health and partners, and distributed to facilities based on regional disease burden by Central Public Health Laboratory (CPHL) using allocation lists	Managed by Zambia Medicines and Medical Supplies Agency. Facilities determine needs and order test kits using electronic logistics management information system (eLMIS). Drugs distributed using a push system
Data system	Paper-based; hospital-based electronic medical record in some facilities	Electronic - Google form	Paper-based; currently working on electronic reporting	Diagnostic data: electronic – Surveillance Outbreak Response Management and Analysis System (SORMAS). Treatment data: paper-based; electronic medical records in some health facilities	Electronic – DHIS2 patient tracker; paper-based tracker at hub facilities. Improved data reporting coverage from January 2024 onwards.	Diagnostic data: Electronic – proprietary system (Laboratory Results Delivery System). Treatment data: Paper based	Electronic Integrated Disease Surveillance and Response (eIDSR) system, REDCap, SmartCare and paper-based registers and clinical forms
National HMIS now includes C-19 antivirals	No	No	No	Yes	Yes	No	No

146

147

148

149

150

151 *Ghana*

152 Ghana has documented 172,075 COVID-19 cases and 1,462 deaths from 2020 through April 2024,  
 153 with three noticeable waves from May-August 2020, January-March 2021 and July-September  
 154 2021.[20] Of note, data from POC-Ag tests, which have been offered in all facilities since 2022, are  
 155 not yet captured in national surveillance data. SARS-CoV-2 vaccines were introduced in March  
 156 2021. The COVID-19 Treatment QuickStart program is managed through the Ghana Health  
 157 Service-Institutional Care Division. Leveraging available POC-Ag tests and a donation of 1,000  
 158 treatment courses through QuickStart, the first test and treat facility was activated – including staff  
 159 members trained and test-and-treat commodities available for patients - in May 2023. Since  
 160 program initiation, through QuickStart, 154 healthcare workers (doctors/physician assistants,  
 161 nurses, pharmacists, medical laboratory scientists, disease control officers, health promotion  
 162 officers) were trained across 16 health facilities (primary, secondary and tertiary level hospitals)  
 163 across 5 regions using a Training of Trainers approach. With support from USAID/RISE and The  
 164 Aurum Institute, Ghana Health Service activated additional facilities, increasing total coverage to  
 165 approximately 54 facilities across 11 of the 16 regions in Ghana. Entry points for screening are  
 166 inpatient wards, outpatient clinics, and emergency rooms.

167

168 *Laos*

169 Laos has documented approximately 207,300 cases of COVID-19 and 750 deaths[21] as of July  
 170 2024, with notable peaks in August 2021 and January 2022. COVID-19 vaccines first arrived in  
 171 Laos in November 2020, becoming available to the public in the first quarter of 2021. The national

COVID-19 test and treat program is managed by the Department of Healthcare and Rehabilitation within the Ministry of Health. Unitaid also provided complementary program support in Laos. Laos received its first donation of nirmatrelvir/ritonavir courses in February 2023; 1,500 courses were donated through QuickStart and the first facility was activated in July 2023. Since program initiation, 238 providers have been trained, and 37 facilities, including central, provincial, and district hospitals, offer treatment across all 18 provinces. The entry points for screening, testing, and linkage to treatment typically occur in emergency rooms and outpatient departments. Key partners supporting the program include the WHO and UNICEF.

180

#### 181 *Malawi*

Malawi has documented 89,564 cases of COVID-19 and 2,687 deaths as of June 2024,[22] with peaks in January 2021, July 2021, January 2022 and January 2024. COVID-19 vaccination was officially launched in March 2021. The COVID-19 test and treat program is led by the Curative and Medical Rehabilitation Directorate of the Ministry of Health. 700 treatment courses were donated through QuickStart in March 2023 and the first facility was activated in July 2023. 12 health facilities across all 3 regions were activated to provide test and treat services. 18 additional facilities were activated through the EPIC program funded by USAID and supported by FHI360. Since the program's inception, 1554 providers from the 12 QuickStart facilities received training. The entry points for screening, testing and treatment include HIV antiretroviral therapy clinic, non-communicable disease, and outpatient clinics/departments. FHI360 is the only additional partner actively involved in the implementation of COVID-19 test and treat programs in Malawi.

193

#### 194 *Nigeria*

195 Nigeria documented 266,313 cases of COVID-19 and 3,155 deaths as of February 2023,[23] with  
 196 peaks from December 2020-February 2021, December 2021-February 2022, and December 2022-  
 197 February 2023. The COVID-19 pandemic response in Nigeria has been driven by the Department  
 198 of Hospital Services of the Federal Ministry of Health and the Nigeria Centre for Disease Control.  
 199 Case Management is domiciled in the Department of Hospital Services of the Federal Ministry of  
 200 Health while the Nigeria Centre for Disease Control which manages diagnostics and other  
 201 surveillance strategies. Nigeria received the first shipment of the COVID-19 vaccines through the  
 202 COVAX Facility in March 2021. 2,600 treatment courses were donated through QuickStart, with  
 203 the first treatment facility activated in June 2023. 1,775 healthcare workers were trained across 69  
 204 primary and secondary health facilities in 3 high-burden states, Rivers, Nasarawa, and Ogun, as  
 205 well as the Federal Capital Territory. Five private facilities were selected to demonstrate the  
 206 feasibility of the test and treat approach in private facilities. Entry points included outpatient, HIV  
 207 treatment, and inpatient clinics, and community facilities. Bidirectional testing was also employed,  
 208 focused on the integration of COVID-19 testing with testing for other diseases such as those seen  
 209 for fever, suspected of malaria, or presenting for routine immunization services, and in febrile  
 210 patients. Other key partners include Institute of Human Virology of Nigeria and the AIDS  
 211 Prevention Initiative in Nigeria. Partners improved case detection through testing across different  
 212 populations such as people living with HIV and tuberculosis.

213

#### 214 *Rwanda*

215 Rwanda has documented 132,489 cases of COVID-19 and 1,466 deaths as of May 2024[24], with  
 216 peaks in COVID-19 cases from December 2020 to February 2021. The country introduced and  
 217 scaled antigen testing for SARS-CoV-2 in January 2021 and COVID-19 vaccines in March 2021.

218 The COVID-19 test and treat program is managed through Public Health Surveillance and  
 219 Emergency Preparedness and Response at the Rwanda Biomedical Center, an implementation  
 220 agency of the Ministry of Health. The first oral antivirals arrived in the country in June 2022  
 221 (procured bilaterally between the government and Pfizer), followed by additional treatment courses  
 222 received through QuickStart in February 2023; a total of 1,000 treatment courses were donated  
 223 through QuickStart and the first facility was activated in March 2023. Since program initiation, an  
 224 estimated 895 providers (medical doctors and nurses) have been trained and 589 hospitals and  
 225 health centers offered COVID-19 test and treat services across the country. The primary criteria to  
 226 treat patients per Rwanda's national guidelines is based on presenting within 5 days of symptom  
 227 onset and having mild/moderate symptoms. Entry points at facilities include outpatient departments  
 228 and the laboratory for inpatients. Rwanda also has conducted several mass screening campaigns in  
 229 the community. Other key partners supporting COVID-19 test and treat include USAID/RISE  
 230 through Jhpiego which activated 8 of the 50 hospitals in the country.

231

## 232 *Uganda*

233 Uganda has documented approximately 170,800 cases of COVID-19 and 3,650 deaths as of May  
 234 2024,[25, 26] with peaks in December 2020, June 2021, July 2022, and December 2022. The first  
 235 batch of COVID-19 vaccines was received in March 2021 via the COVAX Facility. The national  
 236 COVID-19 test and treat program is managed through the Clinical Services Department within the  
 237 Ministry of Health. 500 treatment courses were donated through QuickStart and the first QuickStart  
 238 supported facility was activated in September 2023. Since the program's initiation, 284 providers  
 239 received training and 17 hospitals have offered test and treat programs across 14 of the 15 regions  
 240 in the country. Entry points at facilities include screening in outpatient wards, special clinics and

241 medical in-patient wards; sample collection often took place in designated locations next to the  
 242 laboratory. Other key partners supporting COVID-19 test and treat include the Infectious Diseases  
 243 Institute that supported last mile delivery and pharmacovigilance of the donated  
 244 nirmatrelvir/ritonavir.

245

246 *Zambia*

247 Zambia has recorded approximately 354,126 cases of COVID-19 and 4,079 deaths as of June  
 248 2024[27]. The highest peaks in cases were observed during January 2021, June 2021 and January  
 249 2022. The first batch of vaccines was received in April 2021, via the COVAX Facility. The national  
 250 COVID-19 test and treat program is managed through the Directorate of Infectious Diseases as well  
 251 as the Department of Clinical Care within the Ministry of Health with support from the Zambia  
 252 National Public Health Institute (ZNPHI). 4,000 treatment courses were donated through  
 253 QuickStart; the first QuickStart-supported test and treat facility was activated in December 2022  
 254 (the first of the entire program). Since program initiation, 27 national level trainers, over 133  
 255 facility healthcare providers, and 103 community-based volunteers have been trained, and 36 health  
 256 facilities activated to offer test and treat services across 8 provinces in the country. Two private  
 257 sector facilities were included; the remainder were public sector facilities. COVID-19 test and treat  
 258 entry points at facilities included inpatient departments as well as out-patient departments such as  
 259 emergency, HIV clinics, and TB clinics. Other key partners supporting COVID-19 test and treat  
 260 include ICAP at Columbia and Centre for Infectious Disease and Research in Zambia.

261

## 262 **COVID-19 QuickStart Test and Treat Program Facility Characteristics**

263 Table 2 provides an overview of the facilities implementing test and treat programs through the  
264 QuickStart program. Data were gathered through facility information forms administered at  
265 facilities or through an online portal. In summary, test and treatment programs were implemented at  
266 776 facilities; 238 facilities with QuickStart COVID-19 test-and-treat programs had facility  
267 information data available (in Rwanda, most health centers did not submit facility data). 66.1% of  
268 these facilities were hospitals; the remainder were health centers or clinics. 72.0% were located in  
269 urban or semi-urban areas. 33.5% were supported by partner organizations in addition to the  
270 government. 72.4% were open for COVID-19 testing and treatment 7 days per week. At the time of  
271 data collection, 35.6% offered PCR testing, 65.7% offered antigen testing, and 8.9% offered self-  
272 testing kits for personal use. COVID-19 screening was most commonly offered in outpatient  
273 departments (70.3% of facilities), inpatients (61.4%), the emergency department (60.2%), TB  
274 clinics (53.9%), HIV clinics (51.3%), and non-communicable disease clinics (51.3%). COVID-19  
275 oral antiviral treatment was most commonly offered in outpatient departments (76.3%) followed by  
276 inpatient departments (55.9%).

277 **Table 2. Characteristics of QuickStart-supported Facilities offering COVID-19 Test and Treat Programs**  
278

	Ghana	Laos	Malawi	Nigeria	Rwanda	Uganda	Zambia
Number of QuickStart facilities activated and implementing test and treat as of June 2024	16	37	12	69	589	17	36
Facilities included in analysis below	16	37	12	42 <sup>1</sup>	93 <sup>1</sup>	17	21 <sup>1</sup>
Date of first facility activation	May 2023	July 2023	July 2023	June 2023	March 2023	September 2023	December 2022
Geographic coverage of facilities (e.g., # of regions)	5 of 16 regions	All 17 provinces and capital	All 3 regions	3 of 36 states and capital	All public health facilities in country	14 of 15 regions	8 out of 10 provinces
Total number of staff trained on test and treat	154	238	1554	1,775	895	284	133
Facility type							
Hospital	100.0%	89.2%	50.0%	64.3%	44.1%	100.0%	85.7%
Health Center	0.0%	10.8%	50.0%	31.0%	55.9%	0.0%	14.3%
Clinic	0.0%	0.0%	0.0%	4.8%	0.0%	0.0%	0.0%
Facility location							
Urban	56.3%	89.2%	75.0%	52.4%	20.4%	82.4%	85.7%
Semi-urban	43.8%	10.8%	8.3%	31.0%	18.3%	17.6%	14.3%
Rural	0.0%	0.0%	16.7%	16.7%	57.0%	0.0%	0.0%
Very remote	0.0%	0.0%	0.0%	0.0%	4.3%	0.0%	0.0%
Facility was supported by groups in addition to MOH	18.8%	18.9%	25.0%	38.1%	26.9%	41.2%	28.6%
Facility offered COVID-19 testing and treatment 7 days per week	81.3%	91.9%	16.7%	23.8%	86.0%	82.4%	95.2%
Types of testing available at facilities (select all that apply)							
PCR	81.3%	27.0%	50.0%	21.4%	5.4%	88.2%	57.1%
Antigen	100.0%	94.6%	100.0%	0.0%	100.0%	82.4%	100.0%
Self-testing	0.0%	0.0%	25.0%	0.0%	19.4%	0.0%	0.0%
Where patients are tested for C-19 at facilities (select all that apply)							
Inpatient	56.3%	37.8%	16.7%	31.0%	63.4%	58.8%	71.4%
Outpatient	43.8%	56.8%	58.3%	42.9%	87.1%	76.5%	95.2%



Emergency	50.0%	45.9%	16.7%	23.8%	48.4%	41.2%	76.2%
HIV clinic	18.8%	0.0%	33.3%	35.7%	32.3%	11.8%	38.1%
TB clinic	25.0%	8.1%	16.7%	31.0%	32.3%	23.5%	52.4%
Non-communicable disease clinic	93.8%	2.7%	16.7%	0.0%	38.7%	17.6%	14.3%
Other	25.0%	21.6%	66.7%	54.8%	7.5%	35.3%	23.8%
Where patients are initiated on C-19 treatment at facilities (select all that apply)							
Inpatient	81.3%	51.4%	0.0%	45.2%	58.0%	76.5%	76.2%
Outpatient	81.3%	27.0%	41.7%	100.0%	87.1%	76.5%	85.7%
Emergency	68.8%	5.4%	0.0%	38.1%	40.9%	35.3%	47.6%
HIV clinic	25.0%	2.7%	0.0%	69.0%	30.1%	23.5%	33.3%
TB clinic	25.0%	5.4%	0.0%	33.3%	30.1%	29.4%	28.6%
Non-communicable disease clinic	0.0%	0.0%	0.0%	0.0%	33.3%	23.5%	9.5%
Other	31.3%	48.6%	58.3%	11.9%	0.0%	41.2%	9.5%

279 <sup>1</sup>Data from some facilities in Zambia not available due to them being self-activated / not directly supported by the Clinton Health Access Initiative. Data not  
280 available from 27 facilities in Nigeria with lighter touch program support. Data from Rwanda was collected via a voluntary online survey distributed to all  
281 facilities, and therefore should be considered a convenience sample. 13 facilities nationwide offer PCR testing in Rwanda.  
282  
283

284

## 285 **Testing and Treatment Volumes**

286 Table 3 provides aggregate monitoring and evaluation data from each country from program  
287 initiation through June 2024. Aggregate data were gathered through national data reporting systems  
288 (as described in Table 1) between July and November, 2024. Across the 7 countries, 731,970  
289 people were tested for SARS-CoV-2 at activated test and treat facilities, with the highest volumes  
290 of testing occurring in Rwanda (442,228), Nigeria (193,486), and Zambia (38,426). There were  
291 6,724 positive tests across countries, with the highest numbers of positives in Zambia (3,314),  
292 Rwanda (1,516), and Malawi (691). The percentage of people who tested positive varied  
293 dramatically across countries depending on testing strategy (targeted vs. mass screening campaigns)  
294 and volume. 1,965 people were recorded by test and treat program staff as eligible for treatment.  
295 Eligibility criteria were not consistently documented in the data across all countries, and in some  
296 circumstances, providers used clinical judgment to make prescription decisions, or eligibility was  
297 not initially documented; this explains why in some countries, such as Zambia, the number of  
298 prescriptions is greater than the number recorded in the registers as eligible for  
299 nirmatrelvir/ritonavir. Ultimately, 3,041 people were prescribed nirmatrelvir/ritonavir, with the  
300 largest numbers of prescriptions in Zambia (1,461), Rwanda (786), and Malawi (282).

301

302 **Table 3. COVID-19 Treatment Volumes Achieved in Public Sector Programs from QuickStart Program Initiation through June 2024**  
303

	<b>Ghana</b>	<b>Laos</b>	<b>Malawi</b>	<b>Nigeria<sup>1</sup></b>	<b>Rwanda</b>	<b>Uganda</b>	<b>Zambia</b>	<b>Total</b>
Date first test-and-treat facility activated	May 2023	July 2023	June 2023	June 2023	March 2023	September 2023	December 2022	-
Number of facilities offering test-and-treat	16	37	12	69	589	17	36	776
Number of tests conducted	5,750	26,236	14,697	193,486	444,228	9,147	38,426	731,970
Number of positive patients	289	297	691	362	1,515	256	3,314	6,724
Number of patients recorded as eligible <sup>2</sup>	209	56	295	165	401	130	709	1,965
Number of patients prescribed nirmatrelvir/ritonavir	194	52	282	161	790	106	1,465	3,041

304 <sup>1</sup>Data in Nigeria is through April 2024 due to testing stockouts from May-June 2024.

305 <sup>2</sup>This included presenting within 5 days of symptom onset, mild or moderate disease, and in a high-risk population. Some facilities had limited  
306 documentation of eligibility criteria, particularly in Rwanda where per national guidelines, being in a high-risk population was not always required  
307 for prescription. Zambia did not collect this information for the first 3 months of the program.

308

Figure 1 shows the number of patients testing positive over time by country as well as the number treated over time by country. Treatment numbers were highly variable over time, depending on the number of people who tested positive.

**Figure 1** Number of A) positive SARS-CoV-2 tests per country over time and B) number of people treated with nirmatrelvir/ritonavir over time at activated QuickStart facilities

### **Program Enablers**

Key enablers of smooth program implementation across countries were identified based on communications with key stakeholders, and analysis of program data. First, decentralization of services to lower-level facilities and rapid task shifting to lower health worker cadres allowed for expanded access to services. This approach was more effective to facilitate rapid scale-up in comparison with limiting the provision of services to a small number of specialists. Secondly, access to POC-Ag tests, including self-testing in some country contexts, was another critical factor to facilitate rapid program scale-up. The investments made into scaling rapid diagnostic tests (RDT) before the QuickStart program launch were significant to facilitate a smooth rollout of treatment. For example, the Ghana program leveraged previous experience activating COVID-19 antigen testing facilities across all regions of the country – prior to QuickStart and led by Ghana Health Service with support from the Clinton Health Access Initiative - to expedite test-and-treat program roll-out. Facilities were equipped with human resources and commodities to conduct testing,

allowing training to extensively focus on clinical management. Third, integrated services delivery was critical to rapid implementation. Implementation worked best in facilities where there was a high degree of coordination between the clinical services, diagnostics, and supply chain departments to ensure smooth implementation. Integrated service delivery was less resource intensive and leveraged existing human resources and program structures, ultimately strengthening these structures. For example, Zambia leveraged TB and HIV infrastructure to set up the program leading to establishment of bi-directional screening of COVID-19 and tuberculosis, which ultimately led to better patient care for both disease areas.

In addition to these core factors, facility selection played a role in the ability to quickly launch the program in some contexts. For example, in Malawi, all health facility levels were considered; selection was based on regional disease burden, each facility's ability to conduct testing, presence of doctors on site, and capacity to manage and store stock of drugs and tests, which ultimately led to the initial program rolling out smoothly at facilities best equipped to handle it. However, as noted above, decentralization of services to lower-level facilities is a critical longer-term goal.

Identification of champions to support with introduction and implementation of test and treat was another enabler. For example, in Zambia, there was strong Ministry of Health leadership through the case management specialist who championed the program and continued engagement on the part of the government, which sustained momentum. Finally, in some contexts such as Zambia, community engagement was viewed as an important enabler for program success.

## **Challenges to Program Rollout**

The greatest challenge highlighted by countries in implementing programs was COVID-19 fatigue by both communities and health care workers, as well as the WHO declaration ending the Public Health Emergency of International Concern designation in May 2023. With the reduced number of COVID-19 cases at the time of treatment scale-up, many did not see the importance of test and treat given the timing and other competing priorities. In particular, competing public health emergencies, including cholera in Malawi and Zambia, redirected attention from COVID-19. Relatedly, test commodity availability was a challenge across all countries. Once facilities stocked out of tests or the stock expired, it was challenging to revive testing efforts. For example, in 2022, with Global Fund funding, Ghana procured and supplied COVID-19 POC-Ag testing to all testing facilities across the country. The tests' expiration dates occurred during implementation of the Quick Start program, causing significant stockouts across Quick Start supported facilities for a period of over two months (February to April 2024), which led to gaps in testing and treatment initiation. In Nigeria, there were also test stockouts from May to June 2024. Finally, national surveillance efforts dwindled during the period of program implementation, limiting availability to assess program progress. Without surveillance and testing, this reinforced the sentiment that COVID-19 was no longer a significant problem. Despite these challenges, these 7 countries did successfully roll out COVID-19 test and treat programs within a period of 12 months of donor support.

Two additional countries supported by QuickStart did not roll out the program within this timeframe, due to the impossibility to bring donated nirmatrelvir/ritonavir in country. In one country, South Africa, the drug was deemed not to be a cost-effective treatment for the public sector. In the other, Zimbabwe, delays in obtaining clearing documents in time to bring in drugs with adequate shelf-life led to an inability to advance the program. Finally, another country, Kenya

experienced a delayed rollout of the program, meaning that treatment data were not available as of June 2024.

Learnings from these challenges will be important to incorporate into planning for future pandemic preparedness response.

## **Discussion**

In summary, over a period of 19 months, 7 low- and middle-income countries (Ghana, Laos, Malawi, Nigeria, Rwanda, Uganda, and Zambia) were able to implement COVID-19 test-and-treat programs at 776 health facilities. This included training over 5,000 staff, facilitating a donation of 11,300 courses of nirmatrelvir/ritonavir for treatment, conducting 731,970 SARS-CoV-2 tests, and prescribing nirmatrelvir/ritonavir to 3,041 patients. Despite some challenges around deprioritization of COVID-19 as a public health emergency, programs were able to leverage existing POC-Ag testing programs and approaches including decentralization, task shifting, and integration with existing services to rapidly roll out and scale up a test and treat program.

Limitations of this analysis include that testing and treatment data were gathered through country-level data systems and were in aggregate; therefore, there may be inaccuracies and incomplete data in some contexts, and data cannot be linked to track individual patients across the cascade of care. In addition, this analysis does not include patient outcome data. However, the study team plans to conduct additional analysis on individual-level patient registers in a subset of facilities/countries.

As the COVID-19 landscape evolves and the funding landscape becomes more constrained, many governments are updating their COVID-19 plans to determine response protocols for low-incidence periods and preparedness plans for future surges. This work includes strengthening surveillance systems, developing surge preparedness plans, putting mechanisms in place for increased medical countermeasures as needed, and identifying updated and integrated governance structures for continued program oversight. Learning from experiences rapidly rolling out COVID-19 test and treat programs will be critical to prepare for the next pandemic.

**Acknowledgments:** We acknowledge government partners and healthcare workers in QuickStart program countries for their dedication in implementing this program. We recognize AmeriCares for their collaboration in this consortium as partners involved in the logistics and delivery of donated products. This work was funded by Pfizer, the Open Society Foundations, and the Conrad N. Hilton Foundation. We acknowledge all members of the COVID Treatment QuickStart Consortium: Krishna Udayakumar, Duke Global Health Innovation Center, Elina Urli Hodges, Duke Global Health Innovation Center, Ellen (Nellie) Bristol, Duke Global Health Innovation Center, Emily Macharia, Duke Global Health Innovation Center, Katharine Olson, Duke Global Health Innovation Center, Wenhui Mao, Duke Global Health Innovation Center, Cameron Wolfe, Duke University School of Medicine, Megan Oakes, Duke University School of Medicine, Sarah Gonzales, Duke University School of Medicine, Julie Miller, Duke University School of Medicine, Hayden Bosworth, Duke University School of Medicine, Joseph (Leo) Brothers, Duke Clinical Research Institute, Laine Thomas, Duke Clinical Research Institute, Monica Leyva, Duke Clinical Research Institute, Maria Grau-Sepulveda, Duke Clinical Research Institute, Sharon Stroud, Duke Clinical



Research Institute, Ti Fadika, Duke Clinical Research Institute, Klay Shannon, Duke Clinical Research Institute, Suzanne Zeid, Duke Clinical Research Institute, Michael Merson, Duke Global Health Institute, Shanti Narayanasamy, Duke Global Health Institute

Gary Edson, COVID Collaborative, Elizabeth McCarthy, Clinton Health Access Initiative, Sean Regan, Clinton Health Access Initiative, Jessica Tebor, Clinton Health Access Initiative

Jessica Joseph, Clinton Health Access Initiative, Caroline Boeke, Clinton Health Access Initiative

Nervine Hamza, Clinton Health Access Initiative, Bridget Griffith, Clinton Health Access Initiative, Alan Staple, Clinton Health Access Initiative, Fiona Gambanga, Clinton Health Access Initiative

Hilda Shakwelele, Clinton Health Access Initiative, Alexander Martin-Odoom, Clinton Health Access Initiative, Alida Ngwije, Clinton Health Access Initiative, Chukwuemeka Agwuocha, Clinton Health Access Initiative, Ciru Wanjiru Ndichu, Clinton Health Access Initiative, Lorraine Kabunga, Clinton Health Access Initiative, Maame Nkansaa Asamoah-Amoakohene, Clinton Health Access Initiative, Mwaba Mulenga, Clinton Health Access Initiative, Philip Kimani, Clinton Health Access Initiative, Phyllis Chituku, Clinton Health Access Initiative, Prudence Haimbe, Clinton Health Access Initiative, Sompasong Phongphila, Clinton Health Access Initiative, Garrett Young, Clinton Health Access Initiative, Davis Karambi, Clinton Health Access Initiative, Tamara Mwenifumbo, Clinton Health Access Initiative, Vennie Nabitaka, Clinton Health Access Initiative, Vishal Brijlal, Clinton Health Access Initiative, Yamikani Gumulira, Clinton Health Access Initiative, Folu, Lufadeju, Clinton Health Access Initiative, Brenda Kateera, Clinton Health Access Initiative, Alexio Mangwiro, Clinton Health Access Initiative, Leslie Emegbuonye, Clinton Health Access Initiative, Christian Ramers, Clinton Health Access Initiative, Michelle Gao, Clinton Health Access Initiative, Okechukwu Amako, Clinton Health Access Initiative, Maria Corcorran, Clinton Health Access Initiative, Anthony Bless Dogbede, Clinton Health Access Initiative, Faustina Ofosua

Mintah, Clinton Health Access Initiative, Somsy Dongpadith, Clinton Health Access Initiative, Sabine Umuraza, Clinton Health Access Initiative, Rodrigue Ndayishimiye, Clinton Health Access Initiative

Joseph Kalua, Clinton Health Access Initiative, Nere Otubu, Clinton Health Access Initiative, Simene Sangha, Clinton Health Access Initiative, Oluwatosin Akinwande, Clinton Health Access Initiative, Opeyemi Abudior, Clinton Health Access Initiative, Evarist Twinomujuni, Clinton Health Access Initiative, Robert Kirungi, Clinton Health Access Initiative, Milimo Mweemba, Clinton Health Access Initiative, Megan Knox, Clinton Health Access Initiative, Khamsay Detleuxay, Department of Healthcare and Rehabilitation, Ministry of Health, Lao PDR, Bounxou Keohavong, Food and Drug Department, Ministry of Health, Lao PDR, Viengsakhone Louangpradith, Department of Healthcare and Rehabilitation, Ministry of Health, Lao PDR, Edson Rwagasore, Rwanda Biomedical Center, Pax Axell Karamage, Rwanda Biomedical Center, Lawrence Ofori-Boadu, Ghana Health Service, Moses Mukiibi, Uganda Ministry of Health, Wesley Tomnos, Kenya Ministry of Health, Nyuma Mbewe, Zambia National Public Health Institute, Ijeoma Okoli, Federal Ministry of Health, Nigeria, Norman Lufesi, Malawi Ministry of Health.


## References

1. Center DGHI. QuickStart Consortium [cited 2024 October 1]. Available from: <https://dukeghic.org/our-work/quick-start/>.
2. WHO COVID-19 dashboard 2024 [cited 2024 June 18]. Available from: <https://data.who.int/dashboards/covid19/deaths?n=o>.
3. Rahmani K, Shavaleh R, Forouhi M, Disfani HF, Kamandi M, Oskooi RK, et al. The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis. *Front Public Health*. 2022;10:873596. Epub 20220826. doi: 10.3389/fpubh.2022.873596. PubMed PMID: 36091533; PubMed Central PMCID: PMCPCMC9459165.
4. Ombelet S, Castanares-Zapatero D, Desimpel F, Hulstaert F, Stordeur S, Roberfroid D. Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19 in the era of vaccination and Omicron: An updated meta-analysis. *J Med Virol*. 2024;96(2):e29434. doi: 10.1002/jmv.29434. PubMed PMID: 38376947.
5. Lamb YN. Nirmatrelvir Plus Ritonavir: First Approval. *Drugs*. 2022;82(5):585-91. doi: 10.1007/s40265-022-01692-5. PubMed PMID: 35305258; PubMed Central PMCID: PMCPCMC8933659.
6. COVID-19 Market Dashboard: UNICEF; [cited 2024 August 19]. Available from: <https://www.unicef.org/supply/covid-19-market-dashboard>.
7. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. *N Engl J Med*. 2022;386(15):1397-408. Epub 20220216. doi: 10.1056/NEJMoa2118542. PubMed PMID: 35172054; PubMed Central PMCID: PMCPCMC8908851.
8. Mesfin YM, Blais JE, Kibret KT, Tegegne TK, Cowling BJ, Wu P. Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies. *J Antimicrob Chemother*. 2024;79(9):2119-31. doi: 10.1093/jac/dkaf163. PubMed PMID: 38817046; PubMed Central PMCID: PMCPCMC11368430.
9. Ganatra S, Dani SS, Ahmad J, Kumar A, Shah J, Abraham GM, et al. Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019. *Clin Infect Dis*. 2023;76(4):563-72. doi: 10.1093/cid/ciac673. PubMed PMID: 35986628; PubMed Central PMCID: PMCPCMC9452095.
10. Dryden-Peterson S, Kim A, Kim AY, Caniglia EC, Lennes IT, Patel R, et al. Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study. *Ann Intern Med*. 2023;176(1):77-84. Epub 20221213. doi: 10.7326/M22-2141. PubMed PMID: 36508742; PubMed Central PMCID: PMCPCMC9753458.
11. Narayanasamy S GF, Boeke CE et al. Mixed methods implementation research of oral antiviral treatment for COVID-19 in low and middle-income countries: a study protocol. medRxiv preprint. 2024. doi: <https://doi.org/10.1101/2024.10.25.24316111>.
12. The National Guidelines for COVID-19 Test to Treat in Ghana.
13. Clinical Management of Patients with Novel Coronavirus Disease (COVID-19): Guidance for Laos PDR. 2023.
14. Clinical Management of COVID-19 in Malawi.
15. National Guidelines for the Clinical Management of COVID-19 in Nigeria
16. National Strategy to Scale Up Access to Coronavirus Disease Testing in Nigeria Nigeria Centre for Disease Control; 2020.

17. COVID-19 Clinical Management Guidelines, 5th Edition. Rwanda Biomedical Centre, Republic of Rwanda Ministry of Health; 2023.
18. National Guidelines for Management of COVID-19, 3rd Edition. Republic of Uganda Ministry of Health.
19. Clinical Guidance for Management of Patients with Coronavirus Disease 2019 (COVID-19). Ministry of Health, Republic of Zambia; 2023.
20. COVID-19: Ghana's Outbreak Response Management Updates: Ghana Health Service; [cited 2024 July 15]. Available from: <https://ghs.gov.gh/covid19/latest.php>.
21. Laos COVID-19 Data Dashboard: Laos Ministry of Health; 2024 [cited 2024 July 18]. Available from: <https://moh.gov.la/>
22. Ministry of Health Malawi COVID-19 National Information Dashboard [cited 2024 June]. Available from: <https://covid19.health.gov.mw>.
23. Bi-weekly Epidemiological Report 22 (Epi Week 7-8: 13th-26th February 2023). 2023.
24. Update on COVID-19 17-05-2022. Rwanda: Rwanda Biomedical Center; 2022.
25. COVID-19 Daily Situation Report. 2023.
26. WHO Weekly Bulletin on Outbreaks and Other Emergencies. World Health Organization: Africa Region, 2023 May 21, 2023. Report No.
27. Zambia National Public Health Institute Data. In: Response eIDSa, editor. 2024.

A.

Number of positive COVID-19 test results



B.

Number of individuals prescribed nirmatrelvir/ritonavir




Figure 1